Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New dengue drug could cut fever time and virus levels

NCT ID NCT06006559

Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 16, 2026 · Updated 7 times

Summary

This Phase 2 trial tests an experimental drug called EYU688 in 108 adults with dengue fever. Participants receive either the drug or a placebo to see if it lowers the amount of virus in the blood and shortens fever. The study is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
EYU688
What this could lead to
If it works, this could lead to a new treatment that shortens dengue fever and reduces the amount of virus in the blood.
What could go wrong
This is an early Phase 2 trial with only 108 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 108 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2024

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female, 18 - 60 years old (inclusive). * History or presence of fever (≥ 38°C). At least one of the following criteria indicating dengue infection: * Nausea or vomiting. * Presence of rash, aches or pains including headache, muscle or joint pain. * Onset of fever ≤ 48 hours prior to treatment start. * Positive test on dengue fever. Exclusion Criteria: * Participants with any of abnormalities of clinical laboratory parameters. * Usage of any anticoagulant drugs. * Current significant medical conditions or illness that the investigator considers should exclude the participants, especially those that require continuation of other medications likely to have an interaction with the study drug. * Pregnant or nursing (lactating) women. * Clinical signs and symptoms for severe dengue according to Dengue Guideline (WHO 2009) at screening. * Participants with any of the following abnormalities of clinical laboratory parameters at screening: * Hemoglobin \<12.0 g/dL in males; \<11.0 g/dL in females * Hematocrit \>52 % in males; \>46 % in females * Absolute neutrophil count \<1500/μL * Platelet count \<80,000/mm3 * Creatinine \>165 μmol/L in males; \>130 μmol/L in females * Serum creatine kinase \> 600 U/L * ALT, AST levels more than 3 X upper limit of normal (ULN) * Total bilirubin \>24 μmol/L * Usage of PPIs (proton pump inhibitor) which could affect absorption of EYU688 due to stomach pH value increase up to 48 hours prior to screening. * Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 4 days after stopping of investigational drug. * History or long-QT syndrome, or clinically significant ECG abnormalities, or any of the following ECG abnormalities at screening: * QTcF \> 450 msec (males) * QTcF \> 460 msec (females) Other protocol-defined inclusion/exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dengue are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

dengue disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dengue

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    26 sites in 7 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Novartis Investigative Site

    RECRUITING

    Manaus, Amazonas, 69040-000, Brazil

  • Novartis Investigative Site

    RECRUITING

    Brasília, Federal District, 71635-580, Brazil

  • Novartis Investigative Site

    RECRUITING

    Rio de Janeiro, Rio de Janeiro, 21040-360, Brazil

  • Novartis Investigative Site

    RECRUITING

    Porto Alegre, Rio Grande do Sul, 90560-032, Brazil

  • Novartis Investigative Site

    RECRUITING

    São Caetano do Sul, São Paulo, 09521-160, Brazil

  • Novartis Investigative Site

    RECRUITING

    São José do Rio Preto, São Paulo, 15090 000, Brazil

  • Novartis Investigative Site

    RECRUITING

    Sorocaba, São Paulo, 18040-425, Brazil

  • Novartis Investigative Site

    RECRUITING

    Barranquilla, Atlántico, 080012, Colombia

  • Novartis Investigative Site

    RECRUITING

    Bucaramanga, Santander Department, 681017, Colombia

  • Novartis Investigative Site

    RECRUITING

    Cali, Valle del Cauca Department, 760032, Colombia

  • Novartis Investigative Site

    RECRUITING

    Belagavi, Karnataka, 590010, India

  • Novartis Investigative Site

    WITHDRAWN

    Mumbai, Maharashtra, 400008, India

  • Novartis Investigative Site

    RECRUITING

    Pune, Maharashtra, 411013, India

  • Novartis Investigative Site

    RECRUITING

    Jaipur, Rajasthan, 302017, India

  • Novartis Investigative Site

    RECRUITING

    Chennai, Tamil Nadu, 600113, India

  • Novartis Investigative Site

    RECRUITING

    Kuantan, Pahang, 25200, Malaysia

  • Novartis Investigative Site

    RECRUITING

    Ipoh, Perak, 30450, Malaysia

  • Novartis Investigative Site

    RECRUITING

    Seberang Jaya, Pulau Pinang, 13700, Malaysia

  • Novartis Investigative Site

    RECRUITING

    Miri, Sarawak, 98000, Malaysia

  • Novartis Investigative Site

    RECRUITING

    Kuala Selangor, 68000, Malaysia

  • Novartis Investigative Site

    RECRUITING

    Oaxaca City, 68020, Mexico

  • Novartis Investigative Site

    RECRUITING

    Veracruz, 91855, Mexico

  • Novartis Investigative Site

    RECRUITING

    Singapore, Singapore, 308433, Singapore

  • Novartis Investigative Site

    RECRUITING

    Singapore, 169608, Singapore

  • Novartis Investigative Site

    RECRUITING

    Haiphong, 180000, Vietnam

  • Novartis Investigative Site

    RECRUITING

    Hanoi, 100000, Vietnam

  • Novartis Investigative Site

    RECRUITING

    Ho Chi Minh City, 700000, Vietnam

More trials for these conditions

Other studies related to the condition(s) this trial covers.